Photo of Michael J. Birrer,  MD, PhD

Michael J. Birrer, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4800
Fax: (617) 726-1842

Michael J. Birrer, MD, PhD

Massachusetts General Hospital


  • Professor, Medicine, Harvard Medical School
  • Physician, Medicine, Massachusetts General Hospital
  • Director, Gillette Center for Gynecologic Oncology, Medicine, Massachusetts General Hospital

Research Abstract

The Laboratory of Gynecologic Cancer Research focuses upon the characterization of the molecular biology of gynecologic cancers. The laboratory has identified the genetic alterations of specific oncogenes and tumor suppressor genes in cervical, endometrial and ovarian cancers and correlated these results the clinical behavior of these cancers. In 2000, the laboratory was awarded one of the Director’s Challenge Grants for the genomic analysis of ovarian cancer. The laboratory had conducted a large-scale study of expression profiling of ovarian cancer in collaboration with MDACC, MSKCC, and University of Penn. These efforts have resulted in the characterized the whole genome gene expression profile of ovarian tumors of different histology and grade. This effort identified activated pathways, which are critical for the clinicopathologic characteristics of these tumors. These results have led to the identification of clear cell and mucinous tumor as unique tumors which in turn have fundamentally changed the clinical trails structure at the Gynecologic Oncology Group. This group has now established separate clinical trials for these tumors. Further, utilizing this same approach, the laboratory has shown that low malignant potential tumors of the ovarian (grade 0) to be unique form of serous tumors and therefore requiring a specific therapeutic approach. Based upon this work, the laboratory is beginning a clinical trial using a MEK inhibitor in patients with advanced stage recurrent LMP tumors. More recently, the laboratory completed two larger profiling studies (>300 specimens) on advanced stage papillary serous tumors of the ovary. These studies have generated differential expression gene lists, which can classify these patients into good versus poor prognostic group and identify many potential targets or the therapy and prevention of the disease.

The research direction for the future will focus on three major directions: 1.) characterizing the function and clinicopathologic impact of key genes whose dysregulation is associated with clinical characteristics of ovarian cancer, 2.) characterizing new tumor cellular subsets for their role in tumor formation and the clinical features of the cancer, and 3.) extending these discoveries into the clinic. For the first direction, the laboratory has begun to characterize several genes whose expression predict for the drug resistant phenotype of recurrence ovarian cancer. These genes are unique and involve different aspects of cellular physiology and are both intra and extra cellular. The approach is an in vitro assessment of expression modulation on sensitivity to chemotherapy and then extension into an othortopic model for in vivo validation. In addition, the laboratory is characterizing genes, which are prognostic for the survival of patients with advanced stage papillary serous tumors of the ovary. Finally, other future projects include further characterization of genes, which identify prominent pathways in clear cell and mucinous tumors with the goal being providing mechanistic underpinning of these genes for the unique clinical characteristics of these tumors.

The second direction extends from preliminary work performed on the gene expression patterns of cellular subsets of ovarian tumors. Through collaboration with investigators at MDACC the laboratory has profiled isolated endothelial cells from ovarian tumors and compared them to those of normal ovaries. This has provided a rich list of potential novel targets, which is now under exploration. In a second project, the laboratory is determining the expression of stromal fibroblasts within ovarian tumors compared to those of the normal ovary. This project has the potential to uncover important mechanisms underlying these tumors and potential therapeutic targets. Both of these projects focus on diploid cell populations, which due to their genomic stability may be more optimal therapeutic targets.

The third direction will obviously depend upon the results of the first two, but is ultimately the most important effort. This effort will require a seamless integration of gynecologic oncology research with the clinical management of patients. One of the attractive aspects of the gynecologic oncology efforts at MGH is the high patient volume and expert clinical care. The Gynecologic Cancer Research Program will address important clinical questions within this field. The major clinical questions in ovarian cancer span from the identification of patients at risk for developing ovarian cancer, to the better therapy of patients with advance stage cancer. At present, there are no mechanisms to identify women at risk for the development of sporadic ovarian cancer and this makes early detection or prevention studies essentially impossible. For early stage ovarian cancer, accurate identification of high-risk patients is critical to effectively treat those patients who will recur and minimize toxic effects of therapy on those patients who will not recur. The major clinical questions involving advanced stage disease are identifying risk of recurrence, determining the mechanisms of resistance to chemotherapy and identifying new therapeutic targets. In order to address these questions, a robust clinical trial structure will be implemented. All trials will involve translational research. This would require an effective interaction with biotech companies, large pharmaceutical firms and academic sources of interesting small molecule inhibitors. Finally, a robust genomics facility available and integrated into the programs will assist in making the “bench to bedside” transition of these cutting edge efforts more efficient. This work would require further validation in patient specimens and the monitoring of targets during therapy. While focusing essentially on expression profiling, cgh and other platforms will certainly be very important and applied to clinical samples. It is not difficult to imagine clinical trials, in which the patient’s tumor is analyzed for important known genomic abnormalities will be designed and the patient treated specifically based upon those molecular features.


Powered by Harvard Catalyst
  • Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol 2017; 14:123-136. PubMed
  • Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 2017. PubMed
  • Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun 2017; 8:2166. PubMed
  • Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 2017. PubMed
  • Tsang TY, Wei W, Itamochi H, Tambouret R, Birrer MJ. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. 2017; 8:96482-96495. PubMed
  • Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ, . Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. Journal of the National Cancer Institute 2017. PubMed
  • Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2017. PubMed
  • Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, , Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2017. PubMed
  • Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 2017. PubMed
  • Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 2017. PubMed
  • Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017. PubMed
  • Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 2016. PubMed
  • Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KK, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, , Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KB, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, , Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, , Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TV, Harrington PA, Harris HR, Hauke J, , Hein A, Henderson A, Hildebrandt MA, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FB, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K, , Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LF, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC, , Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PH, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LC, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PD. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 2017. PubMed
  • Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol 2017. PubMed
  • Xiao H, Qi R, Li T, Awuah SG, Zheng Y, Wei W, Kang X, Song H, Wang Y, Yu Y, Bird MA, Jing X, Yaffe MB, Birrer MJ, Ghoroghchian PP. Maximizing Synergistic Activity When Combining RNAi and Platinum-based Anticancer Agents. J Am Chem Soc 2017. PubMed
  • Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 2017; 31:318-332. PubMed
  • Waldron L, Riester M, Ramos M, Parmigiani G, Birrer M. The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. Journal of the National Cancer Institute 2016. PubMed
  • McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016. PubMed
  • Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract 2016. PubMed
  • Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer 2016. PubMed
  • Rauh-Hain JA, Birrer M, Del Carmen MG. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities". Gynecol Oncol 2016. PubMed
  • Dizon DS, Birrer MJ. Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. Journal of the National Cancer Institute 2016. PubMed
  • Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2016; 2:482-90. PubMed
  • Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016; 141:43-8. PubMed
  • Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol 2016; 141:108-12. PubMed
  • Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol 2016; 2:370-2. PubMed
  • Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med 2016; 374:738-48. PubMed
  • van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, Angus L, Hadley K, Lang D, Wei W, Birrer MJ, Trent JO, Leaner VD. Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic. Mol Cancer Ther 2016. PubMed
  • Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, Pépin D. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS ONE 2016; 11:e0156595. PubMed
  • Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. 2015. PubMed
  • Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, Del Carmen MG, Birrer MJ, Cima MJ. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release 2015; 220:358-367. PubMed
  • Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clin Cancer Res 2015. PubMed
  • Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015; 15:668-79. PubMed
  • Richards EJ, Permuth-Wey J, Li Y, Chen YA, Coppola D, Reid BM, Lin HY, Teer JK, Berchuck A, Birrer MJ, Lawrenson K, Monteiro AN, Schildkraut JM, Goode EL, Gayther SA, Sellers TA, Cheng JQ. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. 2015. PubMed
  • Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Target Oncol 2015. PubMed
  • Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A 2015; 112:E4418-27. PubMed
  • Wei W, Birrer MJ. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell 2015; 28:7-9. PubMed
  • Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol 2015. PubMed
  • Castro CM, Im H, Le C, Lee H, Weissleder R, Birrer MJ. Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies. Cancer Metastasis Rev 2015; 34:75-82. PubMed
  • Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res 2015; 21:808-18. PubMed
  • Ghosh D, Bagley AF, Na YJ, Birrer MJ, Bhatia SN, Belcher AM. Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. Proc Natl Acad Sci U S A 2014; 111:13948-53. PubMed
  • Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI. FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene 2014; 33:4424-32. PubMed
  • Dizon DS, Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas. Discov Med 2014; 17:339-45. PubMed
  • Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute 2014. PubMed
  • Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. Journal of the National Cancer Institute 2014. PubMed
  • Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. Better therapeutic trials in ovarian cancer. Journal of the National Cancer Institute 2014; 106:dju029. PubMed
  • Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T, Ohguchi Y, Birrer MJ, Teixeira JM. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis 2014; 35:546-53. PubMed
  • Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 2014; 5:5092. PubMed
  • Birrer MJ. Ovarian cancer: targeting the untargetable. Am Soc Clin Oncol Educ Book 2014; 34:13-5. PubMed
  • Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A 2013; 110:E4978-86. PubMed
  • Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G, . Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer 2013; 23:1528-34. PubMed
  • Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 2013; 123:4435-48. PubMed
  • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49:2972-8. PubMed
  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:1219-25. PubMed
  • Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 2013; 73:5016-28. PubMed
  • Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, , , Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Høgdall E, Høgdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubiński J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013; 45:362-70, 370e1-2. PubMed
  • Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res 2013; 19:809-20. PubMed
  • Holderness Parker N, Donninger H, Birrer MJ, Leaner VD. p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts. PLoS ONE 2013; 8:e66892. PubMed
  • Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS ONE 2013; 8:e53903. PubMed
  • Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, Huttenhower C, Waldron L. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) 2013; 2013:bat013. PubMed
  • Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M, . Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013; 123:517-25. PubMed
  • Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, , , Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, , Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013; 4:1627. PubMed
  • del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012; 127:651-61. PubMed
  • Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 2012; 10:1462-72. PubMed
  • Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30:2654-63. PubMed
  • Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ, Godwin AK. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS ONE 2012; 7:e47086. PubMed
  • King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 2011. PubMed
  • Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, , Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D, , Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, , Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, , Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, , Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, , Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA, . The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011. PubMed
  • Farley J, Smith LM, Darcy KM, Brady MF, Bell J, McGuire W, Birrer MJ. Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study. Gynecol Oncol 2011. PubMed
  • Maritz MF, van der Watt PJ, Holderness N, Birrer MJ, Leaner VD. Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression. Biol Chem 2011. PubMed
  • Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, , Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011. PubMed
  • Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, , Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS ONE 2011; 6:e17617. PubMed
  • Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2010; 29:69-75. PubMed
  • Birrer MJ. The origin of ovarian cancer—is it getting clearer? N Engl J Med 2010; 363:1574-5. PubMed
  • Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer Institute (NCI) clinical trials planning meeting, May, 2009. Int J Gynecol Cancer 2010; 20:1290-1298. PubMed
  • Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, , Beesley J, Webb PM, , , , Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, . A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42:874-9. PubMed
  • Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 2010; 119:114-20. PubMed
  • Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, , , , Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010; 42:880-4. PubMed
  • Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M, Dosaka-Akita H. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer 2010. PubMed
  • Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18:185-97. PubMed
  • Annunziata CM, Birrer MJ. CD157 in ovarian carcinoma: how does it help us? Journal of the National Cancer Institute 2010; 102:1104-5. PubMed
  • Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 2010; 116:3276-84. PubMed
  • Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 2010; 117:429-39. PubMed
  • Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 2010; 70:4005-14. PubMed
  • Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec(R)) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010; 117:248-54. PubMed
  • Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010; 117:125-129. PubMed
  • Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 2010; 12:161-72. PubMed
  • Minig L, Trimble EL, Birrer MJ, Kim KY, Takebe N, Abrams JS. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol 2010; 116:177-80. PubMed
  • Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009; 16:521-32. PubMed
  • Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer 2009; 19 Suppl 2:S21-9. PubMed
  • Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 114:472-9. PubMed
  • Wang XY, Demelash A, Kim H, Jensen-Taubman S, Dakir el H, Ozbun L, Birrer MJ, Linnoila RI. Matrilysin-1 mediates bronchiolization of alveoli, a potential premalignant change in lung cancer. Am J Pathol 2009; 175:592-604. PubMed
  • Kwong J,Chan FL,Wong KK,Birrer MJ,Archibald KM,Balkwill FR,Berkowitz RS,Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009; 11:529-41. PubMed
  • Nosov V,Su F,Amneus M,Birrer M,Robins T,Kotlerman J,Reddy S,Farias-Eisner R. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200:639.e1-5. PubMed
  • Calvisi DF,Donninger H,Vos MD,Birrer MJ,Gordon L,Leaner V,Clark GJ. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009; 69:4629-37. PubMed
  • Farley J,Fuchiuji S,Darcy KM,Tian C,Hoskins WJ,McGuire WP,Hanjani P,Warshal D,Greer BE,Belinson J,Birrer MJ. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 113:341-7. PubMed
  • Singh S,Manda SM,Sikder D,Birrer MJ,Rothermel BA,Garry DJ,Mammen PP. Calcineurin activates cytoglobin transcription in hypoxic myocytes. J Biol Chem 2009; 284:10409-21. PubMed
  • van der Watt PJ,Maske CP,Hendricks DT,Parker MI,Denny L,Govender D,Birrer MJ,Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 124:1829-40. PubMed
  • Chung TK,Cheung TH,Huen NY,Wong KW,Lo KW,Yim SF,Siu NS,Wong YM,Tsang PT,Pang MW,Yu MY,To KF,Mok SC,Wang VW,Li C,Cheung AY,Doran G,Birrer MJ,Smith DI,Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 2008; 124:1358-65. PubMed
  • Leaner VD,Chick JF,Donninger H,Linniola I,Mendoza A,Khanna C,Birrer MJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol 2008; 174:265-75. PubMed
  • Merritt WM,Lin YG,Han LY,Kamat AA,Spannuth WA,Schmandt R,Urbauer D,Pennacchio LA,Cheng JF,Nick AM,Deavers MT,Mourad-Zeidan A,Wang H,Mueller P,Lenburg ME,Gray JW,Mok S,Birrer MJ,Lopez-Berestein G,Coleman RL,Bar-Eli M,Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359:2641-50. PubMed
  • Callahan MJ,Nagymanyoki Z,Bonome T,Johnson ME,Litkouhi B,Sullivan EH,Hirsch MS,Matulonis UA,Liu J,Birrer MJ,Berkowitz RS,Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 2008; 14:7667-73. PubMed
  • Anglesio MS,Arnold JM,George J,Tinker AV,Tothill R,Waddell N,Simms L,Locandro B,Fereday S,Traficante N,Russell P,Sharma R,Birrer MJ,deFazio A,Chenevix-Trench G,Bowtell DD. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6:1678-90. PubMed
  • Lorenzi PL,Llamas J,Gunsior M,Ozbun L,Reinhold WC,Varma S,Ji H,Kim H,Hutchinson AA,Kohn EC,Goldsmith PK,Birrer MJ,Weinstein JN. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008; 7:3123-8. PubMed
  • Park DC,Yeo SG,Wilson MR,Yerbury JJ,Kwong J,Welch WR,Choi YK,Birrer MJ,Mok SC,Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008; 10:964-72. PubMed
  • Bonome T,Levine DA,Shih J,Randonovich M,Pise-Masison CA,Bogomolniy F,Ozbun L,Brady J,Barrett JC,Boyd J,Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008; 68:5478-86. PubMed
  • Sood AK,Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecol Oncol 2008; 110:5-6. PubMed
  • Zhang L,Volinia S,Bonome T,Calin GA,Greshock J,Yang N,Liu CG,Giannakakis A,Alexiou P,Hasegawa K,Johnstone CN,Megraw MS,Adams S,Lassus H,Huang J,Kaur S,Liang S,Sethupathy P,Leminen A,Simossis VA,Sandaltzopoulos R,Naomoto Y,Katsaros D,Gimotty PA,DeMichele A,Huang Q,Butzow R,Rustgi AK,Weber BL,Birrer MJ,Hatzigeorgiou AG,Croce CM,Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008; 105:7004-9. PubMed
  • Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 2008; 109:234-9. PubMed
  • Farley J,Ozbun LL,Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008; 18:538-48. PubMed
  • Landen CN Jr,Birrer MJ,Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26:995-1005. PubMed
  • Zudaire E,Cuesta N,Murty V,Woodson K,Adams L,Gonzalez N,Martinez A,Narayan G,Kirsch I,Franklin W,Hirsch F,Birrer M,Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 2008; 118:640-50. PubMed
  • Irarrazabal CE,Williams CK,Ely MA,Birrer MJ,Garcia-Perez A,Burg MB,Ferraris JD. Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activity. J Biol Chem 2007; 283:2554-63. PubMed
  • Arora S,Wang Y,Jia Z,Vardar-Sengul S,Munawar A,Doctor KS,Birrer M,McClelland M,Adamson E,Mercola D. Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. Genome Biol 2008; 9:R166. PubMed
  • Stany MP,Bonome T,Wamunyokoli F,Zorn K,Ozbun L,Park DC,Hao K,Boyd J,Sood AK,Gershenson DM,Berkowitz RS,Mok SC,Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 2008; 622:23-33. PubMed
  • Whibley CE,McPhail KL,Keyzers RA,Maritz MF,Leaner VD,Birrer MJ,Davies-Coleman MT,Hendricks DT. Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones. Mol Cancer Ther 2007; 6:2535-43. PubMed
  • Kajanne R,Miettinen P,Mehlem A,Leivonen SK,Birrer M,Foschi M,Kahari VM,Leppa S. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 2007; 212:489-97. PubMed
  • Gershenson DM,Birrer M. Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer. Gynecol Oncol 2007; 106:1-3. PubMed
  • Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25:2281-7. PubMed
  • Wu K,Liu M,Li A,Donninger H,Rao M,Jiao X,Lisanti MP,Cvekl A,Birrer M,Pestell RG. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell 2006; 18:755-67. PubMed
  • Lu C,Bonome T,Li Y,Kamat AA,Han LY,Schmandt R,Coleman RL,Gershenson DM,Jaffe RB,Birrer MJ,Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757-68. PubMed
  • Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 2006; 96:1-22. PubMed
  • Samimi G,Ozbun L,Johnson ME,Mok SC,Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers 2007; 23:389-96. PubMed
  • Farley J,Ozbun L,Samimi G,Birrer MJ. Cell cycle and related protein. Dis Markers 2007; 23:433-43. PubMed
  • Mok SC,Kwong J,Welch WR,Samimi G,Ozbun L,Bonome T,Birrer MJ,Berkowitz RS,Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 2007; 23:367-76. PubMed
  • Kelloff GJ,Sullivan DC,Baker H,Clarke LP,Nordstrom R,Tatum JL,Dorfman GS,Jacobs P,Berg CD,Pomper MG,Birrer MJ,Tempero M,Higley HR,Petty BG,Sigman CC,Maley C,Sharma P,Wax A,Ginsberg GG,Dannenberg AJ,Hawk ET,Messing EM,Grossman HB,Harisinghani M,Bigio IJ,Griebel D,Henson DE,Fabian CJ,Ferrara K,Fantini S,Schnall MD,Zujewski JA,Hayes W,Klein EA,DeMarzo A,Ocak I,Ketterling JA,Tempany C,Shtern F,Parnes HL,Gomez J,Srivastava S,Szabo E,Lam S,Seibel EJ,Massion P,McLennan G,Cleary K,Suh R,Burt RW,Pfeiffer RM,Hoffman JM,Roy HK,Wang T,Limburg PJ,El-Deiry WS,Papadimitrakopoulou V,Hittelman WN,MacAulay C,Veltri RW,Solomon D,Jeronimo J,Richards-Kortum R,Johnson KA,Viner JL,Stratton SP,Rajadhyaksha M,Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 2007; 3:1-33. PubMed
  • Farley J,Birrer MJ,Christian MC. The future of phase II trials. Gynecol Oncol 2006; 103:S20-2. PubMed
  • Farley J,Bast RC Jr,Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol 2006; 103:S3-5. PubMed
  • Fountain J,Trimble E,Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol 2006; 103:S23-5. PubMed
  • Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor-{beta} Signaling in Ovarian Cancer. Cancer Res 2006; 66:8404-12. PubMed
  • Birrer MJ. Ovarian cancer: not a borderline issue! Cancer Biol Ther 2006; 5:786-7. PubMed
  • DiFeo A,Narla G,Hirshfeld J,Camacho-Vanegas O,Narla J,Rose SL,Kalir T,Yao S,Levine A,Birrer MJ,Bonome T,Friedman SL,Buller RE,Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12:3730-9. PubMed
  • Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006; 12:690-700. PubMed
  • Nummela P,Yin M,Kielosto M,Leaner V,Birrer MJ,Holtta E. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res 2006; 66:701-12. PubMed
  • Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ.. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 2007; 96:1-22.